DGAP-News: STRATEC Biomedical AG / Key word(s): Dividend
STRATEC proposes increase of dividend to EUR 0.75 per share
Birkenfeld, April 11, 2016
The Board of Management and Supervisory Board of STRATEC Biomedical AG (Frankfurt: SBS; Prime Standard, TecDAX) at their meeting held today approved the recommendation submitted by the Board of Management to propose the payment of a dividend of EUR 0.75 per share for the 2015 financial year for approval by the Annual General Meeting on June 9, 2016 (distribution in previous year: EUR 0.70 per share). Based on the current total of 11,846,280 shares with dividend entitlement, the proposal corresponds to a 7.7% increase in the distribution total to EUR 8.885 million (previous year: EUR 8.248 million). STRATEC continues to follow its shareholder-friendly and continuity-based dividend policy. If approved, this year's dividend would be the twelfth consecutive increase in the distribution to shareholders since dividends were first paid in 2004.
Based on preliminary figures announced on March 15, 2016, STRATEC Biomedical AG increased its sales by 1.4% to EUR 146.9 million in the 2015 financial year. The EBIT margin rose significantly from 16.6% in the previous year to 18.3%. The final audited results for the 2015 financial year will be published on April 14, 2016.
Shares in the company (ISIN: DE000STRA555) are traded in the Prime Standard segment of the Frankfurt Stock Exchange and are listed in the TecDAX select index of the German Stock Exchange.
Further information can be obtained from:
|Company:||STRATEC Biomedical AG|
|Phone:||+49 (0)7082 7916 0|
|Fax:||+49 (0)7082 7916 999|
|Listed:||Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; Terminbörse EUREX|
|End of News||DGAP News Service|